Fig. 4

Association of CD64⁺ Mφ with immune-activated TME and clinical benefit of tislelizumab treatment in the mIHC BEP. A Representative mIHC image for a patient with a high and low CD64⁺ Mφ density. B GSEA illustrating the association of CD64⁺ Mφ density and TME pathways. C Kaplan–Meier overall survival analysis in subgroups defined by density of CD64⁺ Mφ. D Kaplan–Meier overall survival analysis in subgroups defined by proximity of CD8⁺ T cells and CD64⁺ Mφ. Median overall survival was estimated by the Kaplan–Meier method and the log-rank test was used to compare survival curves between defined biomarker subgroups. BEP, biomarker-evaluable population; CI, confidence interval; DAPI, 4’,6-diamidino-2-phenylindole; FDR, false discovery rate; GSEA, gene set enrichment analysis; Mφ, macrophages; mIHC, multiplex immunohistochemistry; NES, normalized enrichment score; Pan-CK, pan-cytokeratin; TME, tumor microenvironment